3Iannello S,Camuto M,Cavaleri A,et al. Effect of met form in treatment on multiple cardiovascular disease risk factors in pa- tients with type 2 diabetes mellitus[J].Metabolism,2004,53:159-162.
1Campbell RK. Glimepiride: role a new sulfonylurea in thetreatmet of type 2 biabetes mellitus. Ann Pharmacother, 1998,32:1044-1049.
2Kramer W, Muller G, Girbig F, et al. Differential interaction ofgllmepiride and glibenclamide with the β-cell sulfonylurea receptor. Ⅱ . Photoaffinity labeling of a 65 Kda protein by [3H]glimepiride . Biochim Biophys Acta, 1994,1191:278-287.
3Muller G, Satoh Y, Geisen K. Extrapancreafic effects of sulfonylureas : a comparison between glimepiride and conventional sulfonylureas. Diabetes Res clin Pract, 1995, 28 (suppl): s115-s121.
4Boer H, Jansen M, Koerts J, et al. Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab, 2004,6 : 114-117.
5Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2diabetesmellitus [J]. JAMA, 2000, 283(13):1695
6Rubins H B, Robins S J, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-densty lipoprotein cholesterol [J]. New Engl J Med 1999, 341(6):410
7Henry R R. Thiazolidinedions. Endocrinol Metab Clin North Am, 1997, 26:553
8Stumvoll M, Gerich J. Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes[J]. Clin Lab Med ,2001,21:31-51.
9Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival[J]. Diabet Nutr Metab , 2000, 13:84-91.
10Sivitz, WI. Lipotoxicity and glucotoxicity in type 2 diabetes effects on development and progression[J]. Post Med , 2001,109:55-59,63-64.
